# EDGAR Filing Document

**Accession Number:** 0001703647
**File Stem:** 0001193125-26-114501
**Filing Date:** 2026-3
**Character Count:** 2821
**Document Hash:** 8f9fdf695d51952571bc1bf9421827cf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-114501.hdr.sgml**: 20260521

**ACCESSION NUMBER**: 0001193125-26-114501

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260318

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Korro Bio, Inc.
- **CENTRAL INDEX KEY:** 0001703647
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 472324450
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 60 FIRST STREET
- **STREET 2:** 2ND FLOOR, SUITE 250
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141
- **BUSINESS PHONE:** 617-468-1999

**MAIL ADDRESS:**
- **STREET 1:** 60 FIRST STREET
- **STREET 2:** 2ND FLOOR, SUITE 250
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Frequency Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20170412

**<u>VIA EDGAR</u>**

March 18, 2026

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Mr. Tim Buchmiller

---

| | |
|:---|:---|
| **Re:** | **Korro Bio, Inc.** |

---

**Acceleration Request for Registration Statement on Form S-3**

**File No. 333-294298**

---

| | |
|:---|:---|
|  **Acceleration Request** | **Acceleration Request** |
|  **Requested Date:** | **March 20, 2026** |
|  **Requested Time:** | **4:15 p.m., Eastern Time** |

---

Dear Mr. Buchmiller:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "**Act**"), Korro Bio, Inc. (the "**Company**") hereby requests that the effective date of the above-referenced registration statement (the "**Registration Statement**") be accelerated to March 20, 2026, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Marianne Sarrazin at (415) 733-6134.

If you have any questions regarding this request, please contact Marianne Sarrazin of Goodwin Procter LLP at (415) 733-6134.

---

| |
|:---|
|  Sincerely, |
|  KORRO BIO, INC. |
| */s/ Ram Aiyar* |
|  Ram Aiyar |
| President, Chief Executive Officer and Interim Chief Financial Officer |
|  Korro Bio, Inc. |

---

cc: Jeffrey Cerio, General Counsel, *Korro Bio, Inc.*

Kingsley L. Taft, Esq., *Goodwin Procter LLP*

Marianne Sarrazin, Esq., *Goodwin Procter LLP*